Veritas Clinical Innovations
Veritas
Confidential enquiry
Sign in

Consulting

Expert advice at the points where development decisions are made.

Six focused offers and one confidential route in. Engagements are scoped in writing, led personally by the named professor and delivered as cited, actionable advice.

Start a confidential enquiryBook an introductory call
Two experts review a molecular structure at a bright table

Offer for companies

What your competitors have already proved, made yours.

Comparator is constructive competitor analysis for pharmaceutical, biotech and diagnostics companies of every size: what the market has already learned, read by clinicians and scientists, tested for transfer and turned into a plan with a measured pilot.

Explore Comparator
Comparator: what competitors have already proved, in forty seconds
01

Therapeutic discovery and development

Independent scientific assessment of a therapeutic concept, from mechanism to development plan, with particular depth in cardiovascular disease and relevance to oncology and respiratory medicine.

Typical questions

  • Is the target rationale supported by human genetic and translational evidence?
  • Which preclinical and early clinical data would make the programme credible to regulators, partners and investors?
  • How should a cardiovascular, oncology or respiratory candidate be positioned against the standard of care and emerging classes?
Learn more
02

Clinical study and trial design

Advice on the design of observational studies and clinical trials: questions, populations, endpoints, comparators and analysis plans that will withstand review.

Typical questions

  • Which primary endpoint answers the question and is feasible in this population?
  • How large, how long, and with what comparator?
  • Which design, parallel, adaptive, platform, pragmatic or registry-based, fits the evidence gap and the budget?
Learn more
03

AI-enabled clinical research

Practical, sceptical advice on using machine learning and large language models in clinical research: where they add value, how to validate them, and how to document their use for ethics committees and regulators.

Typical questions

  • Can AI improve recruitment, phenotyping, adjudication or monitoring in this study, and how would we know?
  • What validation, governance and documentation will ethics committees and regulators expect?
  • How do we use language models in evidence synthesis and study documentation without compromising integrity?
Learn more
04

Scientific due diligence and independent expert opinion

A senior, independent scientific opinion when a decision depends on whether the science holds: investment and partnering due diligence, written expert opinions for boards and counsel, and independent review of institutional research programmes.

Typical questions

  • Does the evidence behind this asset support the claims being made for it?
  • Which risks in the data, the mechanism or the competitive landscape should shape the valuation or the deal terms?
  • What would an independent expert conclude about this programme, in writing and under a confidentiality agreement?
Learn more
05

Clinical trial landscape brief

A fixed-scope brief built from the public trial registries. You name the target, mechanism or indication; we confirm the scope in writing within one working day and deliver the brief within five, with one round of questions included.

Typical questions

  • Which interventional trials are registered for this target, mechanism or indication, at what phase, with which sponsors and in what status?
  • When are the next readouts due, judging from primary completion dates?
  • How do the pivotal trials compare on their endpoints?
Learn more
06

Comparator: constructive competitor analysis

Most competitive intelligence is defensive: it tracks pipelines and warns of threats. Comparator is constructive. We identify what competitors, adjacent markets and other countries have already proved in product design, clinical evidence, claims, pricing and commercial model; test each lesson for evidence, fit, legality and speed; and deliver a transfer plan with a measured pilot.

Typical questions

  • Which competitors or adjacent-market leaders have already solved the problem we are about to spend money on, and what exactly did they prove?
  • Which of their practices can we adopt with the assets we already own, lawfully in our markets, within twelve months?
  • What should we deliberately not copy, and why?
Learn more

Engagement process

Transparent from the first message to the last.

  1. 1

    Confidential enquiry

    Send a short description through the enquiry form or book an introductory call. A mutual NDA can be signed before any substantive discussion.

  2. 2

    Initial review and scoping

    We review the brief, ask the questions that matter and propose a written scope, timeline and fee.

  3. 3

    Agreed expert support

    Work proceeds under a signed engagement letter, led personally by the named professor.

  4. 4

    Delivery and follow-up

    Deliverables are written, cited and discussed with you. A follow-up window for questions is included.

Fees depend on scope and are quoted after the initial review. They are not published.

What Veritas consulting is, and is not

  • Independent expert scientific advice
  • Personal work by the named professor
  • Written, cited deliverables
  • Medical care or advice to patients
  • Regulatory representation or submissions on your behalf
  • Legal advice
  • A guarantee of trial, funding or therapeutic success

Confidential enquiry

Tell us about the project.

A few sentences are enough to start. Please do not include patient-identifiable or study-participant data. We aim to respond within two business days.

What decision are you facing, what exists already, and what would a good outcome look like? At least 30 characters.

Do not upload patient-identifiable data, study-participant data or other sensitive information before a mutual NDA is in place. Aggregated or anonymised material is sufficient for a first review.

PDF, Word, PowerPoint, Excel, OpenDocument or text, up to 15 MB.

Confidential. Stored encrypted within the EEA and deleted after 12 months if no engagement follows.

Prefer to talk first?

Book a confidential 20-minute introductory call with Professor Tomasz Guzik or Professor Marta Czesnikiewicz-Guzik. Calls are confirmed once the professor approves the time.

Book an introductory call